New pill shows promise against Hard-to-Treat cancers

NCT ID NCT05490472

Recruiting now Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JAB-2485 (Aurora A inhibitor, taken orally)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial with only 102 participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

estrogen-receptor positive breast cancer neoplasm small cell lung carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARID1A GENE MUTATION ERΑ+ BREAST CANCER SMALL CELL LUNG CANCER ( SCLC ) SOLID TUMORS TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100101, China
Henry Ford Health System
RECRUITING

Detroit, Michigan, 48202, United States
Jilin Cancer Hospital
RECRUITING

Changchun, Jilin, 130000, China
Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75230, United States
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100101, China
Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, 250117, China
University of Utah Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.